• Ferric carboxymaltose significantly improves hemoglobin levels compared to placebo in iron deficiency anemia.
• FCM is non-inferior to other intravenous iron formulations and has a similar overall safety profile.
• FCM is associated with fewer gastrointestinal adverse events than oral iron supplements.
• The convenience of single-dose FCM administration may enhance patient compliance and healthcare efficiency.